News coverage about Vascular Biogenics (NASDAQ:VBLT) has been trending somewhat positive this week, Accern reports. The research firm identifies negative and positive press coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Vascular Biogenics earned a media sentiment score of 0.23 on Accern’s scale. Accern also assigned news articles about the biopharmaceutical company an impact score of 45.2302738577449 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.

Here are some of the media stories that may have impacted Accern Sentiment’s analysis:

Several equities analysts recently commented on VBLT shares. ValuEngine lowered shares of Vascular Biogenics from a “hold” rating to a “sell” rating in a research report on Tuesday, June 6th. Zacks Investment Research upgraded shares of Vascular Biogenics from a “sell” rating to a “hold” rating in a research note on Wednesday, July 19th. Finally, HC Wainwright set a $11.00 price objective on shares of Vascular Biogenics and gave the stock a “buy” rating in a research note on Tuesday, August 15th. Two research analysts have rated the stock with a sell rating and four have assigned a buy rating to the company’s stock. Vascular Biogenics has a consensus rating of “Hold” and a consensus price target of $12.90.

Vascular Biogenics (VBLT) traded up 6.09% during midday trading on Friday, reaching $6.10. 267,921 shares of the company’s stock traded hands. The stock’s market capitalization is $164.75 million. The company’s 50-day moving average price is $4.93 and its 200 day moving average price is $5.16. Vascular Biogenics has a 52 week low of $3.90 and a 52 week high of $7.25.

Vascular Biogenics (NASDAQ:VBLT) last issued its quarterly earnings data on Monday, August 14th. The biopharmaceutical company reported ($0.18) earnings per share for the quarter, beating the consensus estimate of ($0.19) by $0.01. On average, equities research analysts expect that Vascular Biogenics will post ($0.74) earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: “Vascular Biogenics (VBLT) Receiving Somewhat Positive News Coverage, Study Shows” was originally posted by Watch List News and is the sole property of of Watch List News. If you are reading this piece of content on another publication, it was stolen and republished in violation of U.S. and international copyright law. The original version of this piece of content can be viewed at

About Vascular Biogenics

Vascular Biogenics Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of treatments for cancer. The Company’s program is based on its Vascular Targeting System (VTS) platform technology, which utilizes genetically targeted therapy to destroy newly formed, or angiogenic, blood vessels.

Insider Buying and Selling by Quarter for Vascular Biogenics (NASDAQ:VBLT)

Receive News & Ratings for Vascular Biogenics Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vascular Biogenics Ltd. and related companies with Analyst Ratings Network's FREE daily email newsletter.